Normunity
Normunity is a biotechnology company developing novel anti-cancer therapies targeting untapped biological mechanisms at the interface of the immune system and tumors. Their lead program, NRM-823, is a T cell engager aiming to treat multiple solid tumors and is expected to enter clinical trials in 2025. The company utilizes a proprietary target discovery process to build its pipeline of anti-cancer medicines.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $75M
Date: 13-Jan-2025
Investors: Samsara Biocapital, Enavate Sciences, Pfizer Ventures, Regeneron Ventures, YK Bioventures, Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, Connecticut Innovations
Markets: Biotechnology, Oncology, Immunotherapy, Medical, Therapeutics
HQ: New Haven, Connecticut, United States
Founded: 2020
Website: https://normunity.com/
LinkedIn: https://www.linkedin.com/company/normunity/
Twitter: https://twitter.com/normunity
Crunchbase: https://www.crunchbase.com/organization/normunity
Leave a Comment
Comments
No comments yet.